Advanced search
Publication Cover
Infection and Drug Resistance Volume 15, 2022 - Issue
Submit an article Journal homepage
192
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Drug Resistance Patterns and Trends in Patients with Suspected Drug-Resistant Tuberculosis in Dalian, China: A Retrospective Study

Yuanping PanSchool of Public Health, Dalian Medical University, Dalian, 116000, People’s Republic of ChinaView further author information
,
Yingying YuSchool of Public Health, Dalian Medical University, Dalian, 116000, People’s Republic of ChinaView further author information
,
Jiachen LuSchool of Public Health, Dalian Medical University, Dalian, 116000, People’s Republic of ChinaView further author information
,
Yaohui YiSchool of Public Health, Dalian Medical University, Dalian, 116000, People’s Republic of ChinaView further author information
,
Xiaofeng DouSchool of Public Health, Dalian Medical University, Dalian, 116000, People’s Republic of ChinaView further author information
&
Ling ZhouSchool of Public Health, Dalian Medical University, Dalian, 116000, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 4137-4147 | Published online: 30 Jul 2022

Figures & data

Figure 1 Flowchart for the inclusion of suspected DR-TB patients.

Abbreviations: DR-TB, drug-resistant tuberculosis; NTM, nontuberculous mycobacteria; DST, drug susceptibility testing.
Figure 1 Flowchart for the inclusion of suspected DR-TB patients.

Table 1 Sociodemographic Characteristics of Suspected DR-TB Patients

Table 2 Drug Resistance Patterns in New and Previously Treated Patients with Suspected DR-TB

Figure 2 Trends in new and previously treated DR-TB among patients with suspected DR-TB from 2013 to 2020.

Abbreviation: DR-TB, drug-resistant tuberculosis.
Figure 2 Trends in new and previously treated DR-TB among patients with suspected DR-TB from 2013 to 2020.

Figure 3 Rates and trends of resistance to four first-line drugs in new TB patients from 2013 to 2020.

Abbreviations: INH, isoniazid; RFP, rifampicin; EMB, ethambutol; SM, streptomycin.
Figure 3 Rates and trends of resistance to four first-line drugs in new TB patients from 2013 to 2020.

Figure 4 Rates and trends of resistance to four first-line drugs in previously treated TB patients from 2013 to 2020.

Abbreviations: INH, isoniazid; RFP, rifampicin; EMB, ethambutol; SM, streptomycin.
Figure 4 Rates and trends of resistance to four first-line drugs in previously treated TB patients from 2013 to 2020.

Figure 5 Drug resistance trends in RR-TB and MDR-TB among new TB patients from 2013 to 2020.

Abbreviations: RR-TB, RFP-resistant TB; MDR-TB, multidrug-resistant tuberculosis.
Figure 5 Drug resistance trends in RR-TB and MDR-TB among new TB patients from 2013 to 2020.

Figure 6 Drug resistance trends in RR-TB and MDR-TB among previously treated TB patients from 2013 to 2020.

Abbreviations: RR-TB, RFP-resistant TB; MDR-TB, multidrug-resistant tuberculosis.
Figure 6 Drug resistance trends in RR-TB and MDR-TB among previously treated TB patients from 2013 to 2020.

Table 3 Univariable and Multivariable Logistic Regression Analyses of Sociodemographic Characteristics for MDR-TB Among Suspected DR-TB Patients

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.